Immune Biomarkers for Chronic Inflammation Related Complications in Non-cancerous and Cancerous Diseases

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2017 Jul 5

PMID 28674756

Citations 24

Authors

Yaron Meirow

Michal Baniyash

Affiliations

Soon will be listed here.

Abstract

Chronic inflammation arising in a diverse range of non-cancerous and cancerous diseases, dysregulates immunity and exposes patients to a variety of complications. These include immunosuppression, tissue damage, cardiovascular diseases and more. In cancer, chronic inflammation and related immunosuppression can directly support tumor growth and dramatically reduce the efficacies of traditional treatments, as well as novel immune-based therapies, which require a functional immune system. Nowadays, none of the immune biomarkers, regularly used by clinicians can sense a developing chronic inflammation, thus complications can only be detected upon their appearance. This review focuses on the necessity for such immune status biomarkers, which could predict complications prior to their appearance. Herein we bring examples for the use of cellular and molecular biomarkers in diagnosis, prognosis and follow-up of patients suffering from various cancers, for prediction of response to immune-based anti-cancer therapy and for prediction of cardiovascular disease in type 2 diabetes patients. Monitoring such biomarkers is expected to have a major clinical impact in addition to unraveling of the entangled complexity underlying dysregulated immunity in chronic inflammation. Thus, newly discovered biomarkers and those that are under investigation are projected to open a new era towards combating the silent damage induced by chronic inflammation.

Citing Articles

Applying Neural Networks to Analyse Inflammatory, Sociodemographic, and Psychological Factors in Non-Melanoma Skin Cancer and Colon Cancer: A Statistical and Artificial Intelligence Approach.

Mercut R, Ciurea M, Trasca E, Ionescu M, Mercut M, Radulescu P Diagnostics (Basel). 2024; 14(23).

PMID: 39682667 PMC: 11640483. DOI: 10.3390/diagnostics14232759.

Predicting response to immunotherapy in gastric cancer via assessing perineural invasion-mediated inflammation in tumor microenvironment.

Li X, Wang Y, Zhai Z, Mao Q, Chen D, Xiao L J Exp Clin Cancer Res. 2023; 42(1):206.

PMID: 37563649 PMC: 10416472. DOI: 10.1186/s13046-023-02730-0.

Genetics of Immune Dysregulation and Cancer Predisposition: Two Sides of the Same Coin.

Matza Porges S, Shamriz O Clin Exp Immunol. 2022; 210(2):114-127.

PMID: 36165533 PMC: 9750831. DOI: 10.1093/cei/uxac089.

Enhancement of the Anti-Inflammatory Activity of NSAIDs by Their Conjugation with 3,4,5-Trimethoxybenzyl Alcohol.

Tziona P, Theodosis-Nobelos P, Papagiouvannis G, Petrou A, Drouza C, Rekka E Molecules. 2022; 27(7).

PMID: 35408503 PMC: 9000480. DOI: 10.3390/molecules27072104.

Imbalances in TCA, Short Fatty Acids and One-Carbon Metabolisms as Important Features of Homeostatic Disruption Evidenced by a Multi-Omics Integrative Approach of LPS-Induced Chronic Inflammation in Male Wistar Rats.

Hernandez-Baixauli J, Abasolo N, Palacios-Jordan H, Foguet-Romero E, Sunol D, Galofre M Int J Mol Sci. 2022; 23(5).

PMID: 35269702 PMC: 8910732. DOI: 10.3390/ijms23052563.

References

Laborde R, Lin Y, Gustafson M, Bulur P, Dietz A . Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14(+)HLA-DR(lo/neg) Cells): The Gateway to Improved Responses. Front Immunol. 2014; 5:147. PMC: 3983500. DOI: 10.3389/fimmu.2014.00147. View

Combe P, de Guillebon E, Thibault C, Granier C, Tartour E, Oudard S . Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma. Oncoimmunology. 2015; 4(5):e1001236. PMC: 4485845. DOI: 10.1080/2162402X.2014.1001236. View

Kanterman J, Sade-Feldman M, Biton M, Ish-Shalom E, Lasry A, Goldshtein A . Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes. Cancer Res. 2014; 74(21):6022-35. DOI: 10.1158/0008-5472.CAN-14-0657. View

Inzucchi S . Diagnosis of diabetes. N Engl J Med. 2013; 368(2):193. DOI: 10.1056/NEJMc1212738. View

Navarro J, Mora C, Maca M, Garca J . Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis. 2003; 42(1):53-61. DOI: 10.1016/s0272-6386(03)00408-6. View

Jin C, Lu L, Zhang R, Zhang Q, Ding F, Chen Q . Association of serum glycated albumin, C-reactive protein and ICAM-1 levels with diffuse coronary artery disease in patients with type 2 diabetes mellitus. Clin Chim Acta. 2009; 408(1-2):45-9. DOI: 10.1016/j.cca.2009.07.003. View

Xi Q, Li Y, Dai J, Chen W . High frequency of mononuclear myeloid-derived suppressor cells is associated with exacerbation of inflammatory bowel disease. Immunol Invest. 2015; 44(3):279-87. DOI: 10.3109/08820139.2014.999937. View

Sade-Feldman M, Kanterman J, Klieger Y, Ish-Shalom E, Olga M, Saragovi A . Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab. Clin Cancer Res. 2016; 22(23):5661-5672. DOI: 10.1158/1078-0432.CCR-15-3104. View

Vaknin I, Blinder L, Wang L, Gazit R, Shapira E, Genina O . A common pathway mediated through Toll-like receptors leads to T- and natural killer-cell immunosuppression. Blood. 2007; 111(3):1437-47. DOI: 10.1182/blood-2007-07-100404. View

10.

Vuk-Pavlovic S, Bulur P, Lin Y, Qin R, Szumlanski C, Zhao X . Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate. 2009; 70(4):443-55. PMC: 2935631. DOI: 10.1002/pros.21078. View

11.

Schneider T, Sevko A, Heussel C, Umansky L, Beckhove P, Dienemann H . Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non-small-cell lung cancer. Clin Exp Immunol. 2015; 180(3):467-74. PMC: 4449775. DOI: 10.1111/cei.12596. View

12.

Scrimini S, Pons J, Agusti A, Clemente A, Sallan M, Bauca J . Expansion of myeloid-derived suppressor cells in chronic obstructive pulmonary disease and lung cancer: potential link between inflammation and cancer. Cancer Immunol Immunother. 2015; 64(10):1261-70. PMC: 11029165. DOI: 10.1007/s00262-015-1737-x. View

13.

Inzucchi S . Clinical practice. Diagnosis of diabetes. N Engl J Med. 2012; 367(6):542-50. DOI: 10.1056/NEJMcp1103643. View

14.

Wroblewski L, Peek Jr R, Wilson K . Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev. 2010; 23(4):713-39. PMC: 2952980. DOI: 10.1128/CMR.00011-10. View

15.

Huang B, Lei Z, Zhao J, Gong W, Liu J, Chen Z . CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett. 2007; 252(1):86-92. DOI: 10.1016/j.canlet.2006.12.012. View

16.

Ban Y, Mai J, Li X, Mitchell-Flack M, Zhang T, Zhang L . Targeting Autocrine CCL5-CCR5 Axis Reprograms Immunosuppressive Myeloid Cells and Reinvigorates Antitumor Immunity. Cancer Res. 2017; 77(11):2857-2868. PMC: 5484057. DOI: 10.1158/0008-5472.CAN-16-2913. View

17.

Bergenfelz C, Larsson A, von Stedingk K, Gruvberger-Saal S, Aaltonen K, Jansson S . Systemic Monocytic-MDSCs Are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer Patients. PLoS One. 2015; 10(5):e0127028. PMC: 4439153. DOI: 10.1371/journal.pone.0127028. View

18.

Gross G, Eshhar Z . Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy. Annu Rev Pharmacol Toxicol. 2016; 56:59-83. DOI: 10.1146/annurev-pharmtox-010814-124844. View

19.

Gustafson M, Lin Y, New K, Bulur P, Patrick ONeill B, Gastineau D . Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol. 2010; 12(7):631-44. PMC: 2940665. DOI: 10.1093/neuonc/noq001. View

20.

Huang Q, Shen H, Shui G, Wenk M, Ong C . Emodin inhibits tumor cell adhesion through disruption of the membrane lipid Raft-associated integrin signaling pathway. Cancer Res. 2006; 66(11):5807-15. DOI: 10.1158/0008-5472.CAN-06-0077. View